Fingeraftryk
Dyk ned i forskningsemnerne om 'Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial'. Sammen danner de et unikt fingeraftryk.- Sorter
- Vægt
- Alfabetisk
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
Mogens K. Boisen*, Camilla B. Holst, Nicola Consalvo, Olivier L. Chinot, Julia S. Johansen
*Corresponding author af dette arbejde